14 results
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
11 Sep 23
Regulation FD Disclosure
9:16am
, clonal diversity and persistence NCT05573035 *Potential to expand into additional tumor types mTPI-2, modified toxicity probability interval 2; NSCLC
DEF 14A
w30wserfb
28 Apr 22
Definitive proxy
4:11pm
10-K
nsuae73z
29 Mar 22
Annual report
4:20pm
S-8
EX-99.3
roxo1 9lamz
21 Jun 21
Registration of securities for employees
5:08pm
424B4
3nigiz0pu yufcdae0
18 Jun 21
Prospectus supplement with pricing info
12:00am
S-1/A
ebkcadv81
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
EX-10.3
zwkb9etb a6ogmx
9 Jun 21
IPO registration (amended)
7:12am
S-1
cp672m6tmg6n9ict7
25 May 21
IPO registration
5:28pm
DRS/A
jtv7q
12 May 21
Draft registration statement (amended)
12:00am
DRS
9solsbt8wxzcjrg7
12 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next